Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin with TACE, Lenvatinib, and Pembrolizumab for Unresectable HCC
NCT06896396Phase 2Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Icaritin in hepatocellular carcinoma (HCC). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06896396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896396.